Looking for Rimonabant online Acomplia, Riobant, Slimona, Rimoslim, and Zimulti information and ordering of this new popular anorectic anti-obesity drug? We've got you covered right here with the latest news information and ordering of rimonabant and the name brand information that go along with generic rimonabant.
Acomplia, zimulti, rimonabant
| Product Name | Product Description | Price | Order link |
| Acomplia, zimulti, rimonabant |
84 Tabs |
$ 109.00 | ORDER |
| Acomplia, zimulti, rimonabant |
56 Tabs |
$ 135.00 | ORDER |
| Acomplia, zimulti, rimonabant |
28 Tabs |
$ 59.00 | ORDER |
Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a BMIgreater than 30.Sanofi-Synthelabo, is a new drug thas has shown great promise in trials for the treatment of obesity and related metabolic risk factors. Rimonabant is already on the market in Europe, being sold under the trade name Acomplia , and is awaiting approval in the United States.
If you want to get Acomplia in United States you will get the package under the generic name Rimonabant.
Rimonabant Acomplia zimulti works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System) , believed to play a critical role in the regulation of food intake and energy expenditure. The receptors are present on the surfaces of many cells throughout the body, including fat cells — which are involved in lipid and glucose metabolism — and those in the hypothalamus, the brain region that is thought to determine appetite.
Acomplia, zimulti, rimonabant
| Product Name | Product Description | Price | Order link |
| Acomplia, zimulti, rimonabant | 84 Tabs |
$ 109.00 | ORDER |
| Acomplia, zimulti, rimonabant | 56 Tabs |
$ 135.00 | ORDER |
| Acomplia, zimulti, rimonabant | 28 Tabs |
$ 59.00 | ORDER |
Cannabinoids, chemical compounds produced by your body, latch on to the CB1 receptors, which are overactive in overweight and obese individuals, sending out a signal that prompts people to eat more. Researchers wondered whether a drug that halted this action might curb appetite, and in 2001, the first animal study was conducted at the National Institute of Alcohol Abuse and Alcoholism in Bethesda, Md. In the study, genetically altered mice that lacked cannabinoid receptors ate less than their litter mates, even after 18 hours of fasting. When the normal mice were given rimonabant, which blocked their CB1 receptors, the mice reduced their food intake. In 2002, Sanofi-Synthelabo began human tests. If you want another good diet pill, then phentermine might be your best bet.
Acomplia works by selectively targeting and blocking the CB1 receptors, helping
normalize the over-activation of the EC system and making hunger or cigarette
pangs more manageable. Much of the excitement about Acomplia stems from early
results suggesting that the blocking of signals that control cravings not only
facilitates weight loss, but that it also improves cardiovascular/ metabolic
risk factors in overweight/obese patients.In the RIO-Lipids trial, weight loss
was accompanied by a decrease in waist size of 3.4 inches demonstrating a significant
reduction in abdominal obesity, an independent marker for heart disease.Dramatic
improvements also were reported in lipid profile with a 23% increase in HDL-cholesterol
(good cholesterol) and a 15% decrease in triglycerides.Improvements in glucose
tolerance and insulin levels were also reported. Approximately half of the patients
diagnosed at the start of the study with metabolic syndrome, who received the
higher 20 mg daily dose of Acomplia, no longer had this condition at the conclusion
of the trial.
Acomplia, zimulti, rimonabant
| Product Name | Product Description | Price | Order link |
| Acomplia, zimulti, rimonabant | 84 Tabs |
$ 109.00 | ORDER |
| Acomplia, zimulti, rimonabant | 56 Tabs |
$ 135.00 | ORDER |
| Acomplia, zimulti, rimonabant | 28 Tabs |
$ 59.00 | ORDER |
Much of the excitement about Acomplia /(Rimonabant) Zimulti stems from early results suggesting that it not only facilitates weight loss , but that it also helps patients significantly improve their lipid and glucose profiles.
In the RIO-Lipids trial, weight loss was accompanied by a decrease in waist size of 3.4 inches demonstrating a significant reduction in abdominal obesity, an independent marker for heart disease.
Dramatic improvements also were reported in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides.
Improvements in glucose tolerance and insulin levels were also reported. Approximately half of the patients diagnosed at the start of the study with metabolic syndrome, who received the higher 20 mg daily dose of Acomplia, no longer had this condition at the conclusion of the trial.
Here are some other good rimonabant acomplia zimulti sites.